Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma

BACKGROUND: Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease is commonly excluded from prospective clinical trials. Ovarian carcinosarcoma i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zibetti Dal Molin, Graziela, Abrahão, Carina Meira, Coleman, Robert L., Maluf, Fernando Cotait
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098839/
https://www.ncbi.nlm.nih.gov/pubmed/30147940
http://dx.doi.org/10.1186/s40661-018-0063-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098839/
https://www.ncbi.nlm.nih.gov/pubmed/30147940
http://dx.doi.org/10.1186/s40661-018-0063-3

Ejemplares similares